Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ
Cancer. 2012 118 (24): 6055-62

PMID: 22674198 · PMCID: PMC3934426 · DOI:10.1002/cncr.27668

MeSH Terms (18)

Aged Aged, 80 and over Carcinoma, Renal Cell Disease Progression Female Follow-Up Studies Humans Kidney Neoplasms Male Middle Aged Neoplasm Staging Phosphorylcholine Prognosis Protein Kinase Inhibitors Proto-Oncogene Proteins c-akt Salvage Therapy Survival Rate Vascular Endothelial Growth Factor A

Connections (2)

This publication is referenced by other Labnodes entities:

Links